

Acquisition Opportunity

Active Pharmaceutical Ingredients (API) Development Facility



Eisai Inc. has made the strategic decision to market and sell its Active Pharmaceutical Ingredients (API) development manufacturing facility located in Andover, Massachusetts. This 60,000 SF facility on 26 acres is located 30 miles north of Boston's Logan International Airport and includes two development suites with pilot scale capacity including the capability for manufacturing highly potent compounds. PharmaBioSource Realty, LLC, has been exclusively retained by Eisai to market the facility.

The Opportunity:

The Eisai API facility contains two separate pilot plants as well as a kilo lab plus the required supporting infrastructure for isolation and purification of diverse and high potency APIs. The state-of-the-art API facility represents an investment of over \$50M. Acquisition of the Eisai API site would provide:

- Access to a state-of-the-art facility for the development of diverse and high potency APIs (OEB Level 3).
- The potential to utilize the pilot plant to develop new APIs and for technology transfer purposes.
- Access to a skilled Life Sciences work force.
- Excellent site infrastructure with opportunities for expansion of the manufacturing areas.



Highlights of the facilities include:

- Pilot Plant # 1:
 - 100L glass-lined stainless steel reactor with cryogenic capabilities (-60 to +200°C).
 - 200L and 400L glass-lined carbon steel reactors.
 - 100L and 200L reactors equipped with Hastelloy C-22 charge ports for contained solids charging.
- Pilot Plant # 2:
 - 100L Hastelloy C-22 reactor with charge ports and cryogenic capabilities (-80 to +200°C).
 - 200L and 400L glass-lined carbon steel reactors with Hastelloy C-22 charge ports.
- Kilo Lab:
 - Includes 10, 15, 30, 50 and 100L portable glass reactors and a 50L fixed glass reactor system.
 - Two walk in hoods with “plug in” utilities allowing operational flexibility.
- Filtration and drying equipment / capabilities in both Pilot Plants and the Kilo Lab.
- Chromatography and flexible unit operations suites.
- Quality Control and Analytical laboratories.
- Excellent utility infrastructure including redundancy of key systems.



Interested parties should contact PharmaBioSource Realty, LLC, the exclusive listing agent for this opportunity, for more information regarding an acquisition of this Andover, Massachusetts-based API development manufacturing facility from Eisai.

For further information, please contact:

Sean P. McKee
Technical Information
Cell: 484.686.0123

smckee@pharmabiosource.com

Joe Tarantino
Real Estate
Phone: 610.293.0900

jtaranino@pharmabiosource.com

No representation or warranty, express or implied, is given by Eisai Inc., PharmaBioSource Realty, their respective advisers or any of their respective directors or employees or any other person as to the accuracy or completeness of the contents of this summary information. The only representations and warranties that will be made are those that may eventually be included in a definitive agreement to the proposed sale, if any. Neither this summary nor any of the information contained in it shall form the basis of any contract for the sale of the facility or any part of the facility or assets, nor does it constitute an offer, invitation or inducement to purchase or acquire any shares or assets in the facility or any interest in it.